The Metrics That Matter in Direct-to-Patient Strategies

Key Takeaways

• Speed of therapy initiation reduces patient friction.
• Data on coverage and affordability informs program adjustments.
• Conversion rates and refill adherence measure DTP effectiveness.
• Integration with existing access programs enhances overall patient experience.
• Real‑time insights enable flexible response to policy changes.

Summary

Jordan Armstrong, VP of Business Development at AssistRx, highlighted that speed and data are the core metrics for evaluating direct‑to‑patient (DTP) programs. He explained that rapid therapy initiation, combined with insights on patient coverage and affordability, can differentiate DTP from traditional channels. Armstrong also stressed tracking conversion rates, refill adherence, and integration with broader access initiatives to demonstrate real value. By focusing on measurable outcomes, pharma companies can ensure DTP models improve both patient experience and commercial performance.

Pulse Analysis

The direct‑to‑patient (DTP) model is rapidly moving from niche experiments to a mainstream commercial strategy in pharma. As insurers and patients demand faster access, companies that can shave days off the traditional specialty‑pharmacy timeline gain a competitive edge. Speed isn’t just a service metric; it translates into higher initiation rates, lower drop‑off, and stronger brand perception, especially for high‑cost specialty therapies where every day of delay can affect outcomes.

Beyond speed, DTP generates a wealth of real‑time data on patient coverage, cash versus reimbursable pathways, and affordability options. This granular insight allows manufacturers to tailor assistance programs, negotiate better terms with payers, and dynamically adjust pricing strategies. By capturing these metrics at the point of care, firms can close the feedback loop between market access teams and commercial planners, ensuring that affordability solutions are both effective and scalable.

Long‑term success hinges on tracking conversion, refill adherence, and how DTP integrates with existing access and affordability initiatives. High conversion rates signal that patients are not only starting therapy but staying on it, while refill adherence reflects ongoing engagement and therapeutic effectiveness. When these metrics are linked to broader programs—such as copay assistance or value‑based contracts—pharma can demonstrate a holistic impact on patient health and cost efficiency, reinforcing the strategic importance of DTP in modern drug commercialization.